A Possible Reduction in the Renal Clearance of Ciprofloxacin by Fenbufen in Rats

Naora, Kohji; Katagiri, Yuki; Ichikawa, Nobuhiro; Hayashibara, Masakazu; Iwamoto, Kikuo

doi:10.1111/j.2042-7158.1990.tb06563.x

Cited by 13 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cipro¯oxacin concentrations in whole blood, serum, plasma and ultra®ltrate were determined in accordance with the high-performance liquid chromatographic method developed previously by Naora et al (1990). Another high-performance liquid chromatographic method was employed to determine cipro¯oxacin concentrations in the brain.…”

Section: Assaymentioning

confidence: 99%

Distribution of Ciprofloxacin into the Central Nervous System in Rats with Acute Renal or Hepatic Failure

Naora

Ichikawa

Hirano

et al. 1999

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

Pharmacokinetic changes of various drugs have been reported in renal or hepatic failure. The present study employed ciprofloxacin, a quinolone antibiotic having neurotoxic side effects, to assess the influence of these diseases on distribution of ciprofloxacin into the central nervous system (CNS). After intravenous dosing of ciprofloxacin (10-30 mg kg(-1)), ciprofloxacin levels in plasma and brain were measured in normal rats (Wistar, male, 10-week-old) and those with acute renal and hepatic injuries which were induced by uranyl nitrate and carbon tetrachloride (CCl4), respectively. In the uranyl nitrate-treated rats, the plasma elimination half-life of ciprofloxacin was prolonged and the total body clearance was reduced when compared with those in the normal rats. Similar but smaller changes were observed in the CCl4-treated group. Brain levels of ciprofloxacin were significantly increased by both uranyl nitrate and CCl4 treatments. A proportional correlation between serum unbound levels and brain levels of ciprofloxacin was observed in the normal group. However, brain-to-serum unbound concentration ratios of ciprofloxacin were reduced in the rats with renal or hepatic failure. These results suggest that renal failure as well as hepatic failure retards elimination of ciprofloxacin from the blood, leading to elevation of the CNS level, and also that ciprofloxacin distribution in the brain is reduced in these disease states.

show abstract

Section: Assaymentioning

confidence: 99%

Distribution of Ciprofloxacin into the Central Nervous System in Rats with Acute Renal or Hepatic Failure

Naora

Ichikawa

Hirano

et al. 1999

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous experiments demonstrated that fenbufen administered concomitantly with some quinolones was able to induce a reduction in the body clearance of ofloxacin (Katagiri et a1 1989), to prolong the half-lives of ciprofloxacin (Naora et a1 1990b), norfloxacin (Katagiri et al 1989) and enoxacin (Naora et al1990a). Furthermore, it was demonstrated that co-administered fenbufen tended to reduce the renal clearance of ciprofloxacin by about 20% (Naora et al 1990b). This effect was due to inhibition of the active secretion of ciprofloxacin at the renal proximal tubule by a metabolite of fenbufen (Naora et a1 1992).…”

Section: Discussionmentioning

confidence: 99%

Fenbufen Pretreatment Potentiates the Anticonvulsant Activity of CPPene and NBQX in DBA/2 Mice

Sarro

Renne

Nava

et al. 1994

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

The anticonvulsant activity of 3-((+/-)-2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid (CPPene) and 2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxoline (NBQX), two excitatory amino acid antagonists, was studied against audiogenic seizures in DBA/2 mice, following intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration. Maximal anticonvulsant protection was observed 15-30 min following NBQX and 45-180 min after CPPene. Coadministration with fenbufen (20 mg kg-1, i.p.), a non-steroidal anti-inflammatory agent, enhanced and prolonged the anticonvulsant actions of CPPene and NBQX and also potentiated and prolonged the impairment of rotarod performance. The enhancement of the anticonvulsant activity and the prolonged impairment of rotarod performance suggests that fenbufen may have some pharmacokinetic interactions with CPPene and NBQX and that fenbufen is able to increase the brain levels of these excitatory amino acid antagonists. In particular, fenbufen was able to exert a major degree of potentiation of effects of NBQX rather than those of CPPene, suggesting that the chemical structures of these excitatory amino acid antagonists are responsible for the different degree of interactions between CPPene or NBQX and fenbufen. NBQX appears to have a notable similarity with quinolones whilst CPPene does not. Additionally fenbufen may displace CPPene and NBQX from plasma binding sites or inhibit the renal excretion. The present data are also consistent with previous studies showing pharmacokinetic interactions between fenbufen and quinolones.

show abstract

“…However, other studies conducted in the same species have documented an absence of a pharmacokinetic interaction between fenbufen and sparfloxacin, ciprofloxacin, enoxacin, and ofloxacin [342][343][344][345]. In addition, human studies have the documented absence of a pharmacokinetic interaction between ciprofloxacin and fenbufen and between pefloxacin or ofloxacin and ketoprofen [346][347][348].…”

Section: Quinolones and Nsaidsmentioning

confidence: 92%

Quinolones

Guay¹

2011

Drug Interactions in Infectious Diseases

View full text Add to dashboard Cite

Fluoroquinolone (FQ) antimicrobials are among the most commonly used agents in the outpatient and institutional patient care environments. Due to this high frequency of utilization, the potential for deleterious drug-drug interactions with nonantimicrobials is also high. The majority of interactions with the FQs involve deleterious effects on the FQ component. These are also the most clinically-important interactions with these agents. Multivalent cations such as Mg , and other minerals as well as drugs such as sucralfate, lanthanum, sevelamer, and didanosine (the cation-supplemented version of the latter) can substantially reduce FQ bioavailability, leading the subtherapeutic drug concentrations at the infection site and clinical failure. Separation of dose administrations may or may not reduce the magnitude of these interactions. Ciprofloxacin, norfloxacin, and two experimental FQs in clinical trials (pazufloxacin and prulifloxacin) act as moderate cytochrome P450 enzyme inhibitors and may increase serum concentrations of theophylline and caffeine. Warfarin pharmacodynamics are variably affected by the FQs. The pharmacodynamic interactions between NSAIDs and FQs are only relevant if fenbufen is used concurrently with enoxacin or, possibly, prulifloxacin. Caution is warranted if sparfloxacin or moxifloxacin is used concurrently with other medications prolonging the QTc interval or if patients have other risk factors for prolongation of the QTc interval (e.g. abnormal QTc interval pre-treatment, electrolyte abnormalities, use of starvation-liquid diets, or history of heart disease). Fluoroquinolone antimicrobials can be used effectively and safely in the vast majority of patients if the clinician remembers those few drug-drug interactions that are clinically-important.

show abstract

A Possible Reduction in the Renal Clearance of Ciprofloxacin by Fenbufen in Rats

Cited by 13 publications

References 14 publications

Distribution of Ciprofloxacin into the Central Nervous System in Rats with Acute Renal or Hepatic Failure

Distribution of Ciprofloxacin into the Central Nervous System in Rats with Acute Renal or Hepatic Failure

Fenbufen Pretreatment Potentiates the Anticonvulsant Activity of CPPene and NBQX in DBA/2 Mice

Quinolones

Contact Info

Product

Resources

About